Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/25829
TUBERCULOSIS BIOMARKERS DISCOVERY: DEVELOPMENTS, NEEDS, AND CHALLENGES
Biomarcadores
Vacinas
Mycobacterium tuberculosis
Tratamento
Humanos
Author
Affilliation
Western Reserve University. Specialty Care. Pfizer, Groton. Departments of Medicine, Case. Cleveland, OH, USA / University of Medicine and Dentistry of New Jersey. Newark, NJ, USA
National Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USA
Global Health Institute. Ecole Polytechnique Fédérale de Lausanne. Lausanne, Switzerland
Critical Path Institute. Salt Lake City. UT, USA
National Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USA
Karolinska Institute and CAST. Karolinska Hospital. LabMed and MTC. Division of Therapeutic Immunology. Stockholm, Sweden
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Henry M Jackson Foundation-Division of AIDS. Bethesda, MD, USA
University College London. Centre for Clinical Microbiology. Division of Infection and Immunity. London, UK / University of Zambia. University College London Medical School. University Teaching Hospital. Research and Training Programme. Lusaka, Zambia
National Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USA
Global Health Institute. Ecole Polytechnique Fédérale de Lausanne. Lausanne, Switzerland
Critical Path Institute. Salt Lake City. UT, USA
National Institutes of Health, National Institute of Allergy and Infectious Diseases. Laboratory of Parasitic Diseases. Division of AIDS and Immunobiology Section. Bethesda, MD, USA
Karolinska Institute and CAST. Karolinska Hospital. LabMed and MTC. Division of Therapeutic Immunology. Stockholm, Sweden
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Henry M Jackson Foundation-Division of AIDS. Bethesda, MD, USA
University College London. Centre for Clinical Microbiology. Division of Infection and Immunity. London, UK / University of Zambia. University College London Medical School. University Teaching Hospital. Research and Training Programme. Lusaka, Zambia
Abstract
Biomarkers are indispensable to the development of new tuberculosis therapeutics and vaccines. The most robust
biomarkers measure factors that are essential to the underlying pathological process of the disease being treated, and
thus can capture the full eff ects of many types of interventions on clinical outcomes in multiple prospective,
randomised clinical trials. Many Mycobacterium tuberculosis and human biomarkers have been studied over the past
decade. Present research focuses on three areas: biomarkers predicting treatment effi cacy and cure of active
tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses by
vaccination. Many older, non-specifi c markers of infl ammation, when considered in isolation, do not have suffi cient
predictive values for clinical use in tuberculosis. Although no new accurate, tuberculosis-specifi c biomarkers have yet
been discovered, substantial progress has been made in some areas. However, the qualifi cation of biomarkers as a
surrogate for a clinical endpoint in tuberculosis is very challenging, and, for biomarkers that are non-culture-based,
impossible to pursue without the availability of well characterised biobanks containing biospecimens from patients
who have had adequate follow-up to establish long-term treatment outcome. We review progress in tuberculosis
biomarker development and eff orts being made to harness resources to meet future challenges.
Keywords in Portuguese
TuberculoseBiomarcadores
Vacinas
Mycobacterium tuberculosis
Tratamento
Humanos
Share